Menu Search
Equities

Corcept Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
HTD:BRN

Corcept Therapeutics Inc

Actions
  • Price (CHF)62.57
  • Today's Change0.00 / 0.00%
  • Shares traded10.00
  • 1 Year change--
  • Beta0.2640
Data delayed at least 15 minutes, as of Oct 13 2025.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

  • Revenue in USD (TTM)741.17m
  • Net income in USD106.11m
  • Incorporated1998
  • Employees500.00
  • Location
    Corcept Therapeutics Inc101 REDWOOD SHORES PARKWAYREDWOOD CITY 94065United StatesUSA
  • Phone+1 (650) 688-8803
  • Fax+1 (650) 327-3218
  • Websitehttps://www.corcept.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.